Key result
In patients meeting IVUS criteria for optimal stent placement, antiplatelet therapy was associated with a 0% incidence of major clinical events at 30 days.
Why the study?
Does IVUS-guided stent placement followed by antiplatelet therapy prevent adverse clinical events in patients undergoing non-elective Palmaz-Schatz stent placement?
Observational (n=126)
Does IVUS-guided stent placement followed by antiplatelet therapy prevent adverse clinical events in patients undergoing non-elective Palmaz-Schatz stent placement?
IVUS-guided optimal stent placement allows for the safe use of antiplatelet therapy without systemic anticoagulation, resulting in excellent 30-day clinical outcomes.
OBJECTIVE: To test the efficacy of intravascular ultrasound (IVUS)-guided stent placement and to determine the clinical outcome during the first 30 days in those patients who were treated with antiplatelet therapy rather than anticoagulants because they met the IVUS criteria for optimal stent placement. DESIGN: Prospective observational study. PATIENTS: 126 patients with successful, non-elective Palmaz-Schatz stent placement. INTERVENTIONS: IVUS was performed to assess the attachment of stent struts, the coverage of the dissection, and the intrastent minimal lumen area. MAIN OUTCOME MEASURES: Intrastent lumen area, clinical outcome during the first 30 days. RESULTS: In all patients IVUS showed complete apposition and coverage of the dissection. In 23 patients (18%) the IVUS lumen area criterion was achieved. In 75 patients, further balloon dilatation was performed and in 41 IVUS criteria were finally fulfilled. The minimal intrastent lumen area increased from a mean (SD) of 6.81 (1.15) mm2 to 9.56 (2.61) mm2 (P < or = 0.01) between the first and final IVUS investigations. 64 patients (51%) who met the IVUS criteria were treated with aspirin (100 mg) and ticlopidine (250 mg) twice a day. During the first 30 days none of the following events occurred: death, myocardial infarction, repeat intervention, aortocoronary bypass surgery, and subacute stent thrombosis. CONCLUSION: The additional information provided by IVUS examination helped the operator to decide whether further dilatation was needed after a coronary stent had been placed. For patients who met the IVUS criteria for optimal stent placement, antiplatelet therapy was associated with an excellent clinical outcome during the first 30 days.
No takes yet. Share an insight, caveat, or question.
Blasini et al. (1996) conducted an observational in Non-elective Palmaz-Schatz stent placement (n=126). IVUS-guided stent placement and antiplatelet therapy was evaluated on Clinical outcome during the first 30 days (death, myocardial infarction, repeat intervention, aortocoronary bypass surgery, and subacute stent thrombosis). In patients meeting IVUS criteria for optimal stent placement, antiplatelet therapy was associated with a 0% incidence of major clinical events at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: